What Evidence Exists for Ozempic-Related Gastroparesis in North Carolina?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Legal Inquiry

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis—a condition where stomach emptying slows. Decades of pharmacovigilance research have established that certain medications can affect gastrointestinal motility, and recent reports have focused on semaglutide's potential role. This page reviews the current evidence and documented cases related to Ozempic and gastroparesis in North Carolina.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in some formulations, for weight loss. Its mechanism involves slowing gastric emptying, which contributes to glycemic control but also raises concerns about gastrointestinal adverse effects, including gastroparesis. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, and it requires ruling out other causes like diabetes-related autonomic neuropathy or postsurgical changes. The link between Ozempic and gastroparesis is grounded in its pharmacology: GLP-1 receptor agonists delay gastric emptying as a therapeutic effect, but in susceptible individuals, this can become pathological, resulting in symptomatic gastroparesis. Mechanistically, semaglutide activates GLP-1 receptors on gastric smooth muscle and enteric neurons, inhibiting antral contractions and pyloric relaxation, which can lead to prolonged gastric retention. This is supported by postmarketing reports of pulmonary aspiration in patients undergoing procedures under general anesthesia or deep sedation, where residual gastric contents were observed despite adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Such events underscore the potential for severe gastric stasis, a hallmark of gastroparesis.

Clinical Evidence and Adverse Event Data

Clinical trial data from the Ozempic prescribing information reveal a higher incidence of gastrointestinal adverse reactions among treated patients compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 32.7% of patients receiving Ozempic 0.5 mg and 36.4% of those receiving 1 mg, versus 15.3% in the placebo group (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and discontinuation rates due to gastrointestinal adverse reactions were 3.1% for the 0.5 mg dose and 3.8% for the 1 mg dose, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, specific gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), gastroesophageal reflux disease (placebo 0%, 0.5 mg 1.9%, 1 mg 1.5%), and gastritis (placebo 0.8%, 0.5 mg 0.8%, 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not explicitly list gastroparesis as a separate adverse event, the constellation of symptoms—nausea, vomiting, dyspepsia, and delayed gastric emptying—aligns with the clinical presentation of gastroparesis. The absence of a specific warning for gastroparesis in the prescribing information raises questions about the adequacy of warnings regarding this potential risk.

Legal Context: Statute of Limitations in North Carolina

From a risk perspective, patients in North Carolina who developed gastroparesis after using Ozempic may have legal recourse, but they must consider the statute of limitations. In North Carolina, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or reasonably should have been discovered. For product liability claims, the statute of repose may also apply, barring claims after a certain number of years from the product's sale or manufacture. Given that Ozempic was approved by the FDA in 2017, affected patients should consult an attorney promptly to assess their specific timeline. Attorney-related considerations include documenting the date of first Ozempic use, the onset of gastroparesis symptoms, and any medical diagnoses confirming the condition. The timeline between exposure and documented harm is critical: gastroparesis may develop weeks to months after starting Ozempic, and symptoms can persist or worsen even after discontinuation. Patients should gather medical records, including prescriptions, symptom logs, and diagnostic test results, to establish causation. The adequacy of warnings is a central legal issue. The prescribing information does not explicitly warn about gastroparesis, though it notes gastrointestinal adverse reactions and the risk of pulmonary aspiration due to retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This omission may form the basis of a failure-to-warn claim, arguing that the manufacturer did not adequately inform prescribers and patients of the potential for severe gastric stasis leading to gastroparesis.

Summary and Next Steps for Affected Individuals

In summary, the evidence indicates that Ozempic is associated with gastrointestinal adverse reactions that can mimic or cause gastroparesis, and the drug's mechanism of delaying gastric emptying supports a plausible link. The lack of a specific warning for gastroparesis in the prescribing information may be a significant risk factor for affected patients. Those in North Carolina should act promptly to preserve their legal rights, given the three-year statute of limitations from the date of discovery. Consulting with an attorney experienced in pharmaceutical litigation is essential to evaluate the strength of a claim based on the timeline of exposure, diagnosis, and the adequacy of warnings.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including pharmaceutical product liability, is generally three years from the date the injury was discovered or reasonably should have been discovered. For product liability claims, a statute of repose may also apply. It is crucial to consult an attorney promptly to assess your specific timeline.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) can cause delayed gastric emptying as a therapeutic effect, which may progress to gastroparesis in susceptible individuals. Clinical data show a higher incidence of gastrointestinal adverse reactions, and postmarketing reports have noted severe gastric stasis. However, the prescribing information does not explicitly warn about gastroparesis, which may be a legal concern.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.